Romidepsin, a histone deacetylase inhibitor, was investigated in combination with CHOP in a randomised phase III trial conducted by the LYSA group for PTCL, excluding ALK-positive ALCL [36]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.